Breast Cancer Drugs

A new study finds that using two drugs, Herceptin (her-SEPT-in) and Tykerb (TIE-curb), more than doubles the number of women with early breast cancer whose tumors disappear before they are scheduled to have surgery to remove them.
These drugs target a protein that is overproduced in about one-fourth of all breast cancers. In the study, about 450 women getting chemotherapy were also given Herceptin or Tykerb or both drugs. Half of the women on the combination saw their tumors disappear versus only 20 percent of those taking either drug alone.
GlaxoSmithKline PLC makes Tykerb. Roche's Genentech division makes Herceptin. Doctors discussed the study Friday at a conference in San Antonio.

You must be logged in to post comments.

Password (case sensitive):
Remember Me:

Read Comments

Comments are posted from viewers like you and do not always reflect the views of this station.
  • by Liz Location: Holt on Dec 10, 2010 at 08:43 AM
    This article somewhat confuses me. It refers to "early" breast cancer but then references the drug being tested compared to women who underwent chemo. "Early" breast cancer never involves chemo; 'early' means stage 0 or 1. If someone gets chemo, it's a more advanced stage and/or has already spread. (I'm a breast cancer survivor so know a bit about this.)
WILX 500 American Road Lansing, MI 48911 517-393-0110
Copyright © 2002-2016 - Designed by Gray Digital Media - Powered by Clickability 111668629 -
Gray Television, Inc.